SU11274 is widely used in cancer research as a selective inhibitor of the c-Met kinase, a receptor tyrosine kinase often overexpressed or mutated in various tumors. It helps block the HGF (hepatocyte growth factor)-induced signaling pathway, which plays a key role in tumor cell proliferation, survival, migration, and invasion. Due to its inhibitory effect, SU11274 is employed in preclinical studies to investigate the role of c-Met in cancer progression, particularly in lung, breast, liver, and gastric cancers. It is also used to assess the potential of targeted therapies that suppress metastasis and tumor growth in cell culture and animal models. Its application supports the development of more effective kinase inhibitors for oncology.